文献速递乳腺癌

曲妥珠单抗联合每周紫杉醇和卡铂作为HER2阳性乳腺癌新辅助治疗:TRAIN研究

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.
PubMed 文献 · Eur J Cancer · 2017-02-10

TRAIN研究评估不含蒽环类的每周紫杉醇、卡铂联合曲妥珠单抗方案用于II-III期HER2阳性乳腺癌新辅助治疗的疗效与安全性。111例入组,108例可评估,病理完全缓解率为43%(95%CI:33-52)。中位随访52个月,3年无事件生存率88%(95%CI:82-94),3年总生存率92%(95%CI:88-98)。

要点

  • 不含蒽环类的每周紫杉醇+卡铂+曲妥珠单抗方案病理完全缓解率达43%。
  • 中位随访52个月,3年无事件生存率88%,3年总生存率92%。
  • 常见3-4级不良事件为中性粒细胞减少(67%)和血小板减少(43%)。

核心结论

  • 不含蒽环类的每周紫杉醇、曲妥珠单抗和卡铂新辅助方案在HER2阳性乳腺癌中高效且毒性可控。

研究设计与样本

  • 研究纳入II期或III期HER2阳性乳腺癌患者,接受每周紫杉醇70 mg/m2、曲妥珠单抗2 mg/kg(负荷剂量4 mg/kg)和卡铂AUC=3 mg ml-1 min,共24周;第7、8、15、16、23和24周仅给予曲妥珠单抗不加化疗。
  • 主要终点为手术切除标本的病理完全缓解,定义为乳腺和腋窝无浸润性肿瘤细胞。
  • 111例患者入组,108例可评估主要终点。

主要发现

  • 病理完全缓解率为43%(95%CI:33-52)。
  • 中位随访52个月,3年无事件生存率为88%(95%CI:82-94),3年总生存率为92%(95%CI:88-98)。
  • 最常见的3-4级不良事件为中性粒细胞减少(67%)和血小板减少(43%)。
  • 不足5%的患者发生发热性中性粒细胞减少。
  • 新辅助治疗期间未观察到症状性左心室收缩功能障碍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To determine the efficacy and safety of an anthracycline-free neo-adjuvant regimen consisting of weekly paclitaxel, carboplatin and trastuzumab in HER2-positive breast cancer. PATIENTS AND METHODS: Patients with stage II or III HER2-positive breast cancer received weekly paclitaxel ([P], 70 mg/m2), trastuzumab ([T], 2 mg/kg, loading dose 4 mg/kg) and carboplatin ([C], AUC = 3 mg ml-1 min) for 24 weeks. In weeks 7, 8, 15, 16, 23 and 24, trastuzumab was administered without chemotherapy. The primary end-point was pathologic complete response in the surgical resection specimen, defined as the absence of invasive tumour cells in breast and axilla. RESULTS: One hundred and eleven patients were included in the study, and 108 were evaluable for the primary end-point. The pathologic complete response rate was 43% (95% confidence interval [CI]: 33-52). Median follow-up was 52 months, and the 3-year event-free survival was 88% (95% CI: 82-94), and the 3-year overall survival was 92% (95% CI: 88-98). The most common grade 3-4 adverse events were neutropenia (67%) and thrombocytopenia (43%). Less than five percent of patients experienced febrile neutropenia. No symptomatic left ventricular systolic dysfunction was observed during neo-adjuvant treatment. CONCLUSION: An anthracycline-free neo-adjuvant regimen of weekly paclitaxel, trastuzumab and carboplatin is highly effective in HER2-positive breast cancer with manageable toxicity.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Ramshorst MS, van Werkhoven E, Mandjes IAM, et al. Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. Eur J Cancer. 2017. PMID: 28335887. doi:10.1016/j.ejca.2016.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。